Results 161 to 170 of about 104,093 (313)

Causal effect of gut microbiota on occurrence of herpes zoster and postherpetic neuralgia, and role of Tyzzerella 3

open access: yesEuropean Journal of Medical Research
Background Previous research has established connections between gut microbiota, immune modulation, and several virus-related diseases. However, no study has explored the relationships between gut microbiota and herpes zoster and postherpetic neuralgia ...
Xin Zhang   +9 more
doaj   +1 more source

Stewardship of Molecular Diagnostics in Transplant Viral Infections

open access: yesTransplant Infectious Disease, EarlyView.
ABSTRACT The transplant environment requires special considerations when testing for viral infections as immunosuppression results in atypical infection profiles. Microbes otherwise considered commensals or causing mild disease can lead to severe infections in transplant environments. Therefore, guidelines tend to recommend broader microbial testing in
Scott Sugden   +3 more
wiley   +1 more source

Drastic Response to Olaparib in a Patient With Metastatic Castration‐Resistant Prostate Cancer Harboring BRCA2 Alterations and Near‐Threshold Tumor Mutational Burden

open access: yesIJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction BRCA2 alterations and high tumor mutational burden (TMB‐H) are responsible for prostate cancer; however, their co‐occurrence is uncommon, and evidence for PARP inhibition in the castration‐sensitive setting remains limited. We describe a case of metastatic castration‐resistant prostate cancer (CRPC) harboring both biomarkers ...
Kotaro Yokota   +6 more
wiley   +1 more source

Global and regional estimates of vaccine-associated herpes zoster and their related vaccines from 1969 to 2023

open access: yesScientific Reports
Vaccine-induced immunosuppression can reactivate the varicella-zoster virus, potentially leading to the development of herpes zoster. However, the literature on this topic is inconsistent, resulting in limited clarity.
Jinyoung Jeong   +18 more
doaj   +1 more source

Retrospective analysis of cutaneous immune‐related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA‐B*51:01 allele

open access: yesCancer, Volume 132, Issue 3, 1 February 2026.
ABSTRACT Background While immune checkpoint inhibitors (ICIs) have shown significant efficacy, a common side effect is cutaneous immune‐related adverse events (irAEs). This study focuses on exploring the association between specific human leukocyte antigen (HLA) alleles and the development of cutaneous irAEs in melanoma patients undergoing ICI ...
Mckenzie DiLeo   +12 more
wiley   +1 more source

A Case of Recurrence of Severe Depressive Disorder With Flu—Neuroinflammatory Basis of Depressive Disorder

open access: yesProgress in Neurology and Psychiatry, Volume 30, Issue 1, February 2026.
ABSTRACT This case highlights a relapse of major depressive disorder in an elderly man following a flu‐like illness, with clinical features and laboratory findings supporting a possible inflammatory contribution. It emphasises the relevance of the inflammatory theory of depression, especially in individuals with late‐life depression and recent immune ...
Nauman Malik, Mohamed A. Mohamed
wiley   +1 more source

Filgotinib Is an Effective and Safe Treatment Option for Difficult‐To‐Treat Ulcerative Colitis: Real‐World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry

open access: yesUnited European Gastroenterology Journal, Volume 14, Issue 1, February 2026.
ABSTRACT Background Filgotinib is a preferential Janus kinase 1 (JAK‐1) inhibitor registered for the treatment of ulcerative colitis (UC). Real‐world effectiveness of filgotinib, especially for difficult‐to‐treat (DTT, failure of ≥ 2 prior advanced therapies) patients, has been scarcely reported.
M. R. Naber   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy